Positive patient-reported outcomes data expand on the efficacy benefits of trastuzumab deruxtecan and pembrolizumab
Two studies show that quality of life was maintained or improved with new treatments for advanced breast cancer
Sibylle Loibl receives the ESMO Breast Cancer 2022 Award
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer
Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time
Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients
Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib
Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations
Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC
Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings
Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis
How long should we give immunotherapy for?
The length of immunotherapy course for metastatic lung cancer was arbitrarily set at 2 years in clinical trials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking
How can we continue to improve outcomes for our patients with lung cancer?
Advances made in the treatment of advanced lung cancer are now being introduced at earlier stages of disease
Poziotinib does not meet the expectations to target insertion mutations in HER2 exon 20 in NSCLC
The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor